Eganelisib

A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
125 patients (estimated)
Sponsors
Stelexis BioSciences
Tags
PI3K Inhibitor, Randomization, High Risk
Trial Type
Treatment
Last Update
SparkCures ID
2185
NCT Identifier
NCT06533761

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.